Journal article

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

Susan O'Brien, Jeffrey A Jones, Steven E Coutre, Anthony R Mato, Peter Hillmen, Constantine Tam, Anders Osterborg, Tanya Siddiqi, Michael J Thirman, Richard R Furman, Osman Ilhan, Michael J Keating, Timothy G Call, Jennifer R Brown, Michelle Stevens-Brogan, Yunfeng Li, Fong Clow, Danelle F James, Alvina D Chu, Michael Hallek Show all

The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2016

Grants

Funding Acknowledgements

We thank the patients who participated in the study, their supporters, and the investigators and clinical research staff from the study centres. This manuscript was developed with editorial support from Luana Atherly-Henderson from Nexus Global Group Science LLC and funded by Pharmacyclics LLC, an AbbVie Company.